Document is current
Any future updates will be listed below
-
Authors
Hernández-Sánchez, Alberto https://orcid.org/0000-0002-6601-3096
Villaverde Ramiro, Ángela https://orcid.org/0000-0002-7337-7218
Sträng, Eric
Turki, Amin T. https://orcid.org/0000-0003-1347-3360
Abáigar, María
Versluis, Jurjen https://orcid.org/0000-0003-2372-1663
Thomas, Ian
Sobas, Marta
Martínez Elicegui, Javier https://orcid.org/0000-0001-5294-6162
Castellani, Gastone https://orcid.org/0000-0003-4892-925X
Benner, Axel
Azibeiro, Raúl https://orcid.org/0000-0002-3382-3674
Tettero, Jesse M. https://orcid.org/0000-0002-0811-0824
Mecklenbrauck, Rabea https://orcid.org/0009-0005-9374-300X
Martínez-López, Joaquín https://orcid.org/0000-0001-7908-0063
Pratcorona, Marta
Mills, Ken I. https://orcid.org/0000-0002-6362-4481
Sanz, Guillermo https://orcid.org/0000-0002-2767-8191
Voso, Maria Teresa https://orcid.org/0000-0002-6164-4761
Sören, Lehmann
Röllig, Christoph https://orcid.org/0000-0002-3791-0548
Thiede, Christian https://orcid.org/0000-0003-1241-2048
Metzeler, Klaus H. https://orcid.org/0000-0003-3920-7490
Döhner, Konstanze https://orcid.org/0000-0002-2261-9862
Heuser, Michael https://orcid.org/0000-0001-5318-9044
Haferlach, Torsten https://orcid.org/0000-0003-0196-2837
Valk, Peter JM https://orcid.org/0000-0002-8857-9461
Russell, Nigel
Hernández-Rivas, Jesús María https://orcid.org/0000-0002-9661-9371
Huntly, Brian https://orcid.org/0000-0003-0312-161X
Ossenkoppele, Gert
Döhner, Hartmut https://orcid.org/0000-0003-2116-5536
Bullinger, Lars https://orcid.org/0000-0002-5890-5510
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CM23/00101)
Deutsche Forschungsgemeinschaft (FU 356/12-1)
Deutsche Krebshilfe (70115737)
- License Information
-
More Information
Article History
Received: 24 July 2025
Revised: 22 November 2025
Accepted: 12 December 2025
First Online: 14 January 2026
Competing interests
: ATT: Consultancy for CSL Behring, Maat Pharma, Biomarin, and Onkowissen; travel reimbursements from Neovii Biotech and Novartis. MS: honoraria from Novartis, Celgene, AOP Orphan, and AbbVie. KHM: honoraria from AbbVie, Bristol Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Otsuka; research funding from AbbVie. RA: honoraria from Astellas, Bristol Myers Squibb, Incyte, and Novartis. MP: honoraria from Novartis. GS: honoraria from Takeda and has participated in Ad-Boards from Novartis, Celgene, AbbVie, Helsinn, and Takeda. CR: honoraria from AbbVie, Astellas, Bristol-Meyer-Squibb, Daiichi Sankyo, Jazz, Janssen, Novartis, Otsuka, Pfizer, Servier; institutional research funding from AbbVie, Astellas, Novartis, Pfizer. CT: co-owner and CEO of AgenDix GmbH and has received lecture fees and/or participated in Ad-Boards from Novartis, Jazz Pharmaceuticals, Astellas, Janssen, Illumina; research funding from Novartis, Bayer. KD: honoraria from Novartis, Jazz Pharmaceuticals, AbbVie; has participated in Ad-Boards from Novartis, Bristol Myers Squibb, Jazz Pharmaceuticals, AbbVie; research funding from Novartis, Astellas, Agios, Bristol Myers Squibb, Kronos. MH: honoraria from Astellas, Daiichi Sankyo, Janssen, Miltenyi, Otsuka, Qiagen, Servier, and has participated in Ad-Boards from AbbVie, AvenCell, Ascentage Pharma, Bristol Myers Squibb, Janssen, Jazz Pharmaceuticals, LabDelbert, Novartis, Pfizer, Servier; research funding from AbbVie, Bayer Pharma AG, Jazz Pharmaceuticals, Glycostem, Karyopharm, PinotBio, Servier, Toray. TH: current employment at Munich Leukemia Laboratory, with part ownership. JMHR: honoraria from Bristol Myers Squibb, Pfizer, Amgen, Celgene, GSK, Novartis; Advisory role for Bristol Myers Squibb, Pfizer, Amgen, Celgene, Novartis, Janssen, Roche, AbbVie, AstraZeneca, Beigene, Lilly, Gilead, Takeda, Jazz Pharmaceuticals, Rovi, Incyte; research funding from Bristol Myers Squibb, Celgene, Novartis. BH: honoraria from Pfizer, Bristol Myers Squibb, Novartis; research funding from AstraZeneca. GO: honoraria from AbbVie, Jazz Pharmaceuticals, Astellas, Gilead, Bristol Myers Squibb, Servier, Roche. HD: Advisory role for AbbVie, Agios, Amgen, Astellas, AstraZeneca, BERLIN-CHEMIE, Bristol Myers Squibb, Celgene, GEMoaB, Gilead Sciences, Janssen, Jazz Pharmaceuticals, Novartis, Syndax; research funding from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Kronos-Bio, Novartis. LB: honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Otsuka, Pfizer, Roche, and Sanofi; research funding from Bayer, Jazz Pharmaceuticals.
